Plasmodium vivax Malaria Market is projected to reach USD 2.14 billion by 2034

The global Plasmodium vivax (P. vivax) Malaria Market was valued at USD 1.21 billion in 2024 and is projected to reach USD 2.14 billion by 2034, growing at a CAGR of 6.0% during 2025-2034. Growth is driven by increasing disease surveillance in endemic regions, expanding access to radical cure therapies, rising investment in malaria elimination programs, and ongoing R&D in anti-relapse drugs and vaccines.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70960

Plasmodium vivax is the most widespread malaria parasite globally and is characterized by its ability to form dormant liver-stage hypnozoites, leading to recurrent relapses even after blood-stage clearance. This relapse biology makes control and elimination significantly more challenging compared to Plasmodium falciparum. P. vivax disproportionately affects Asia-Pacific, Latin America, and the Horn of Africa, contributing to substantial morbidity, productivity loss, and healthcare burden.

Key Market Highlights
• 2024 Market Size: USD 1.21 billion
• 2034 Forecast: USD 2.14 billion
• CAGR (2025-2034): 6.0%
• Largest Segment: Blood-stage antimalarials (chloroquine, ACTs)
• Fastest-Growing Segment: Radical cure therapies targeting hypnozoites (primaquine, tafenoquine)

Epidemiology & Clinical Insights
1. Global Burden
• P. vivax causes ~6.5 million cases annually.
• Dominant malaria species in:
o India
o Indonesia
o Papua New Guinea
o Afghanistan
o Brazil
o Colombia
• Increasing concern due to emerging chloroquine resistance, especially in Southeast Asia.
2. Biological Characteristics
• Ability to form hypnozoites → causes relapses weeks to months later.
• Lower parasitemia levels make detection challenging.
• More likely to cause anemia than mortality, but carries significant economic burden.
3. Symptoms
• Fever
• Chills
• Sweats
• Fatigue & malaise
• Anemia
• Splenomegaly

Market Growth Drivers
1. Scale-Up of Malaria Elimination Programs
WHO, Global Fund, Gates Foundation, and national malaria control programs are pushing for P. vivax elimination.
2. Increased Adoption of Radical Cure
• Primaquine remains first-line therapy.
• Tafenoquine (single-dose radical cure) is expanding adoption due to better adherence.
3. Advances in Diagnostic Technologies
Including:
• High-sensitivity rapid diagnostic tests (hsRDTs)
• Loop-mediated isothermal amplification (LAMP)
• PCR testing for low-density infections
4. Growing Awareness of G6PD Deficiency Testing
Required to safely administer primaquine and tafenoquine, driving demand for point-of-care G6PD diagnostics.
5. Rising R&D into Novel Antimalarials
Pipeline molecules target:
• Liver-stage parasites
• Transmission-blocking
• Chloroquine-resistant strains

Market Restraints
• G6PD deficiency limits broad use of radical cure therapies
• Diagnostic difficulty due to low parasitemia
• Chloroquine resistance increasing in some regions
• Limited healthcare infrastructure in endemic areas

Market Opportunities
1. Single-Dose Antirelapse Therapies
Tafenoquine adoption expected to grow significantly in endemic countries.
2. P. vivax-Specific Vaccine Development
Early-stage candidates targeting CSP, RBP, and other liver-stage antigens.
3. Integration of Molecular Diagnostics
PCR and LAMP platforms for elimination campaigns.
4. Expansion of G6PD Rapid Testing
Essential for safe treatment rollout of hypnozoite-targeting drugs.
5. Vector Control Innovations
New insecticides, spatial repellents, and gene-drive technologies.

Segmentation Overview
By Treatment Type
• Blood-stage antimalarials
o Chloroquine
o Artemisinin-based combination therapies (ACTs)
• Radical cure therapies
o Primaquine
o Tafenoquine
• Supportive care medications
• Vaccine (pipeline)

By Diagnostic Type
• Rapid diagnostic tests (RDTs)
• Microscopy
• Molecular tests (PCR, LAMP)
• G6PD deficiency testing devices

By End User
• Hospitals
• Malaria clinics
• Community health programs
• Research institutes
• NGOs and public-health agencies

Explore Full Report here: https://exactitudeconsultancy.com/reports/70960/plasmodium-vivax-malaria-market

Regional Insights
Asia Pacific - Largest Market
India, Indonesia, and PNG represent the highest disease burden. Major focus on radical cure adoption and molecular diagnostics.
Latin America - Strong Elimination Efforts
Brazil, Colombia, and Peru actively expanding screening and treatment networks.
Middle East & Central Asia - Growing Awareness
Afghanistan and Pakistan show high P. vivax prevalence.
Sub-Saharan Africa - Emerging Focus
Ethiopia and the Horn of Africa have significant P. vivax caseloads, historically under-recognized.
North America & Europe - Research Hubs
Minimal disease burden but strong research investments in vaccines and drug development.

Competitive Landscape
Leading companies and organizations include:
• GSK (tafennoquine)
• Sanofi (antimalarial formulations)
• Novartis (ACTs)
• Pfizer
• Access Bio (RDTs)
• SD Biosensor
• Abbott (G6PD testing)
• PATH, Medicines for Malaria Venture (MMV)
• Academic research programs focused on vaccine development

Recent Market Developments
• Increased deployment of tafenoquine in Asia-Pacific and Latin America
• Rollout of point-of-care quantitative G6PD tests
• New molecular diagnostic tools for pre-elimination regions
• R&D funding for liver-stage and transmission-blocking antimalarials
• Progress in P. vivax vaccine antigen discovery

Future Outlook (2025-2034)
The P. vivax malaria market will expand steadily as:
• Radical cure therapies achieve wider adoption
• G6PD testing becomes standard practice
• Diagnostic sensitivity improves for low-density infections
• Malaria elimination strategies intensify globally
By 2034, the market is expected to reach USD 2.14 billion, driven by therapeutic innovation, strengthened public-health campaigns, and expanded diagnostic coverage.

This report is also available in the following languages : Japanese (三日熱マラリア原虫), Korean (플라스모디움 비박스 말라리아), Chinese (间日疟原虫疟疾), French (Plasmodium vivax Paludisme), German (Plasmodium vivax Malaria), and Italian (Malaria da Plasmodium Vivax), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/70960

Our More Reports:

Antibiotics Market
https://exactitudeconsultancy.com/reports/50024/antibiotics-market

U.S. Antibiotics Market
https://exactitudeconsultancy.com/reports/50402/u-s-antibiotics-market

Benzathine Penicillin G Market
https://exactitudeconsultancy.com/reports/51892/benzathine-penicillin-g-market

Animal Antibiotics And Antimicrobials Market
https://exactitudeconsultancy.com/reports/51905/animal-antibiotics-and-antimicrobials-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.